The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
When cancer cells mutate, they produce small peptides called neoantigens. Because neoantigens remain relatively unique to ...
Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved ...
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback